Pirlindole HCl

Pirlindole, a reversible inhibitor of monoamine oxidase A (RIMA), has been developed and used primarily as an antidepressant compound in Russia. Structurally and pharmacologically, it is similar to metralindole. Pirlindole has received approval for the treatment of depression in several European and non-European countries. Its oral absolute bioavailability ranges from 20% to 30%, mainly due to significant first-pass metabolism. In rats, the oral Tmax varies between 2.5 and 6 hours, while in dogs, it ranges from 0.8 to 2 hours.